<DOC>
	<DOC>NCT00890552</DOC>
	<brief_summary>This open-label trial will evaluate the use of lenalidomide; melphalan; and dexamethasone (MDR) to treat newly diagnosed or relapsed AL amyloidosis, over the course of nine 28-day cycles.</brief_summary>
	<brief_title>A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL Amyloidosis</brief_title>
	<detailed_description>The study will evaluate the 3-drug combination of lenalidomide; melphalan; and dexamethasone (MDR) as the absence of disease progression or toxicity, patients will complete nine 28-day cycles of MDR therapy, with the option of continuing treatment with lenalidomide as single-agent. Patients received up to nine cycles of treatment, with the option to continue on lenalidomide as a single agent if they responded to treatment.</detailed_description>
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>INCLUSION CRITERIA Newly diagnosed or relapsed AL amyloidosis Biopsyproven amyloidosis with evidence of an underlying plasma cell dyscrasia abnormal clonal dominance of plasma cells in the bone marrow detection of a monoclonal gammopathy by immunofixation electrophoresis of serum and/or urine an abnormal serum free light chain or ratio, or AL fibrils seen on biopsy) Measurable disease defined by an abnormal serumfree light chain or monoclonal protein by immunofixation proteinuria ≥ 0.5 g/day, cardiac involvement with interventricular septal thickness ≥ 15 mm hepatomegaly in the absence of congestive heart failure with elevated alkaline phosphatase Age ≥ 18 years at the time of signing the informed consent form. All previous cancer therapy must have been discontinued at least 4 weeks prior to treatment in this study ECOG performance status of ≤ 3 at study entry Laboratory test results: Absolute neutrophil count ≥ 1.0 x 10e9 / L Platelet count ≥ 75 x 10e9 / L Creatinine clearance ≥ 15 mL/ minute Total bilirubin ≤ 2fold upper limits of normal Diseasefree of prior malignancies (excluding multiple myeloma) for ≥ 3 years with exception of: currently treated basal cell squamous cell carcinoma of the skin carcinoma "in situ" of the cervix or breast. Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test Females of childbearing potential must either: commit to continued abstinence from heterosexual intercourse acceptable methods of birth control and agree to ongoing pregnancy testing Men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy All study participants must be registered into the mandatory RevAssist program, and able to comply with its requirements Able to take aspirin (81 mg) daily • Understand and voluntarily sign an informed consent form Able to adhere to the study visit schedule and other protocol requirements EXCLUSION CRITERIA Any serious medical condition that would prevent the subject from signing the informed consent form Pregnant breastfeeding females Use of any other experimental drug or therapy within 28 days of baseline Known hypersensitivity to thalidomide Erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs Any prior use of lenalidomide Concurrent use of other anticancer agents or treatments Known positivity for human immunodeficiency virus HIV)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>